The University of Chicago Header Logo

Connection

David T. Rubin to Tumor Necrosis Factor-alpha

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Tumor Necrosis Factor-alpha.
David T. Rubin
Connection Strength
4.017
Tumor Necrosis Factor-alpha
  1. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
    View in: PubMed
    Score: 0.510
  2. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.474
  3. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
    View in: PubMed
    Score: 0.458
  4. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul; 21(7):1709-18.
    View in: PubMed
    Score: 0.392
  5. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.381
  6. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
    View in: PubMed
    Score: 0.362
  7. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.311
  8. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21; 18(3):197-204.
    View in: PubMed
    Score: 0.309
  9. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
    View in: PubMed
    Score: 0.133
  10. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
    View in: PubMed
    Score: 0.126
  11. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.084
  12. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.073
  13. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.061
  14. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.038
  15. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.038
  16. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.037
  17. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 04; 70(4):796-802.
    View in: PubMed
    Score: 0.035
  18. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.034
  19. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 01; 53(1):e1-e11.
    View in: PubMed
    Score: 0.031
  20. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.029
  21. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
    View in: PubMed
    Score: 0.027
  22. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.026
  23. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.025
  24. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.